Literature DB >> 17609261

Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120.

Xin Wang1, Tomofumi Uto, Takami Akagi, Mitsuru Akashi, Masanori Baba.   

Abstract

The mainstream of recent anti-AIDS vaccines is a prime/boost approach with multiple doses of the target DNA of human immunodeficiency virus type 1 (HIV-1) and recombinant viral vectors. In this study, we have attempted to construct an efficient protein-based vaccine using biodegradable poly(gamma-glutamic acid) (gamma-PGA) nanoparticles (NPs), which are capable of inducing potent cellular immunity. A significant expansion of CD8+ T cells specific to the major histocompatibility complex class I-restricted gp120 epitope was observed in mice intranasally immunized once with gp120-carrying NPs but not with gp120 alone or gp120 together with the B-subunit of cholera toxin. Both the gp120-encapsulating and -immobilizing forms of NPs could induce antigen-specific spleen CD8+ T cells having a functional profile of cytotoxic T lymphocytes. Long-lived memory CD8+ T cells could also be elicited. Although a substantial decay in the effector memory T cells was observed over time in the immunized mice, the central memory T cells remained relatively constant from day 30 to day 238 after immunization. Furthermore, the memory CD8+ T cells rapidly expanded with boosting with the same immunogen. In addition, gamma-PGA NPs were found to be a much stronger inducer of antigen-specific CD8+ T-cell responses than nonbiodegradable polystyrene NPs. Thus, gamma-PGA NPs carrying various HIV-1 antigens may have great potential as a novel priming and/or boosting tool in current vaccination regimens for the induction of cellular immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17609261      PMCID: PMC2045421          DOI: 10.1128/JVI.00489-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

Review 1.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Analysis of poly(D,L-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro.

Authors:  M E Christine Lutsiak; Deborah R Robinson; Conrad Coester; Glen S Kwon; John Samuel
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

Review 3.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

4.  Virus-specific cellular immune correlates of survival in vaccinated monkeys after simian immunodeficiency virus challenge.

Authors:  Yue Sun; Jörn E Schmitz; Adam P Buzby; Brianne R Barker; Srinivas S Rao; Ling Xu; Zhi-Yong Yang; John R Mascola; Gary J Nabel; Norman L Letvin
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

5.  Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

Authors:  K J Maloy; A M Donachie; D T O'Hagan; A M Mowat
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

6.  Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.

Authors:  Nilu Goonetilleke; Stephen Moore; Len Dally; Nicola Winstone; Inese Cebere; Abdul Mahmoud; Susana Pinheiro; Geraldine Gillespie; Denise Brown; Vanessa Loach; Joanna Roberts; Ana Guimaraes-Walker; Peter Hayes; Kelley Loughran; Carole Smith; Jan De Bont; Carl Verlinde; Danii Vooijs; Claudia Schmidt; Mark Boaz; Jill Gilmour; Pat Fast; Lucy Dorrell; Tomas Hanke; Andrew J McMichael
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

7.  Induction of mucosal IgA following intravaginal administration of inactivated HIV-1-capturing nanospheres in mice.

Authors:  Masaki Kawamura; Taichi Naito; Masamichi Ueno; Takami Akagi; Katsuya Hiraishi; Izumi Takai; Masahiko Makino; Takeshi Serizawa; Kazuhisa Sugimura; Mitsuru Akashi; Masanori Baba
Journal:  J Med Virol       Date:  2002-03       Impact factor: 2.327

8.  Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

Authors:  A Moore; P McGuirk; S Adams; W C Jones; J P McGee; D T O'Hagan; K H Mills
Journal:  Vaccine       Date:  1995-12       Impact factor: 3.641

9.  Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity.

Authors:  Tomofumi Uto; Xin Wang; Katsuaki Sato; Misako Haraguchi; Takami Akagi; Mitsuru Akashi; Masanori Baba
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

10.  Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.

Authors:  Norman L Letvin; Yue Huang; Bimal K Chakrabarti; Ling Xu; Michael S Seaman; Kristin Beaudry; Birgit Korioth-Schmitz; Faye Yu; Daniela Rohne; Kristi L Martin; Ayako Miura; Wing-Pui Kong; Zhi-Yong Yang; Rebecca S Gelman; Olga G Golubeva; David C Montefiori; John R Mascola; Gary J Nabel
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

View more
  14 in total

Review 1.  A review of nanotechnological approaches for the prophylaxis of HIV/AIDS.

Authors:  Abhijit A Date; Christopher J Destache
Journal:  Biomaterials       Date:  2013-05-28       Impact factor: 12.479

Review 2.  Design opportunities for actively targeted nanoparticle vaccines.

Authors:  Tarek M Fahmy; Stacey L Demento; Michael J Caplan; Ira Mellman; W Mark Saltzman
Journal:  Nanomedicine (Lond)       Date:  2008-06       Impact factor: 5.307

3.  Uptake of biodegradable poly(γ-glutamic acid) nanoparticles and antigen presentation by dendritic cells in vivo.

Authors:  Tomofumi Uto; Masaaki Toyama; Yosuke Nishi; Takami Akagi; Fumiaki Shima; Mitsuru Akashi; Masanori Baba
Journal:  Results Immunol       Date:  2012-12-03

4.  Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells.

Authors:  Heidi A Schreiber; Jozsef Prechl; Hongquan Jiang; Alla Zozulya; Zsuzsanna Fabry; Ferencz Denes; Matyas Sandor
Journal:  J Immunol Methods       Date:  2010-02-26       Impact factor: 2.303

5.  Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(gamma-glutamic acid) nanoparticles.

Authors:  Takayuki Hamasaki; Tomofumi Uto; Takami Akagi; Mitsuru Akashi; Masanori Baba
Journal:  Clin Vaccine Immunol       Date:  2010-03-10

Review 6.  Emerging nanotechnology approaches for HIV/AIDS treatment and prevention.

Authors:  Tewodros Mamo; E Ashley Moseman; Nagesh Kolishetti; Carolina Salvador-Morales; Jinjun Shi; Daniel R Kuritzkes; Robert Langer; Ulrich von Andrian; Omid C Farokhzad
Journal:  Nanomedicine (Lond)       Date:  2010-02       Impact factor: 5.307

7.  Polylactide-cyclosporin A nanoparticles for targeted immunosuppression.

Authors:  Jamil Azzi; Li Tang; Robert Moore; Rong Tong; Najib El Haddad; Takurin Akiyoshi; Bechara Mfarrej; Sunmi Yang; Mollie Jurewicz; Takaharu Ichimura; Neal Lindeman; Jianjun Cheng; Reza Abdi
Journal:  FASEB J       Date:  2010-06-14       Impact factor: 5.191

8.  Induction of potent adaptive immunity by the novel polyion complex nanoparticles.

Authors:  Tomofumi Uto; Takami Akagi; Mitsuru Akashi; Masanori Baba
Journal:  Clin Vaccine Immunol       Date:  2015-03-25

9.  Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses.

Authors:  Ana Lucia Dominguez; Joseph Lustgarten
Journal:  Vaccine       Date:  2009-11-18       Impact factor: 3.641

Review 10.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.